These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27618260)

  • 1. From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.
    Wu Y; Jiang S; Ying T
    Expert Opin Biol Ther; 2016 Dec; 16(12):1469-1478. PubMed ID: 27618260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds.
    Zajc CU; Salzer B; Taft JM; Reddy ST; Lehner M; Traxlmayr MW
    FEBS J; 2021 Apr; 288(7):2103-2118. PubMed ID: 32794303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
    Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
    Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
    Gross G; Eshhar Z
    Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.
    Krug C; Birkholz K; Paulus A; Schwenkert M; Schmidt P; Hoffmann N; Hombach A; Fey G; Abken H; Schuler G; Schuler-Thurner B; Dörrie J; Schaft N
    Cancer Immunol Immunother; 2015 Dec; 64(12):1623-35. PubMed ID: 26515978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
    Fujiwara K; Masutani M; Tachibana M; Okada N
    Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors.
    Han S; Latchoumanin O; Wu G; Zhou G; Hebbard L; George J; Qiao L
    Cancer Lett; 2017 Apr; 390():188-200. PubMed ID: 28089834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
    Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA
    Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
    Drent E; Themeli M; Poels R; de Jong-Korlaar R; Yuan H; de Bruijn J; Martens ACM; Zweegman S; van de Donk NWCJ; Groen RWJ; Lokhorst HM; Mutis T
    Mol Ther; 2017 Aug; 25(8):1946-1958. PubMed ID: 28506593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobody-based CAR-T cells for cancer immunotherapy.
    Safarzadeh Kozani P; Naseri A; Mirarefin SMJ; Salem F; Nikbakht M; Evazi Bakhshi S; Safarzadeh Kozani P
    Biomark Res; 2022 Apr; 10(1):24. PubMed ID: 35468841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
    Smith EL; Staehr M; Masakayan R; Tatake IJ; Purdon TJ; Wang X; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Riviere I; Liu C; Brentjens RJ
    Mol Ther; 2018 Jun; 26(6):1447-1456. PubMed ID: 29678657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.
    Duan Y; Chen R; Huang Y; Meng X; Chen J; Liao C; Tang Y; Zhou C; Gao X; Sun J
    Cell Mol Life Sci; 2021 Dec; 79(1):14. PubMed ID: 34966954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.
    Murad JM; Graber DJ; Sentman CL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):176-183. PubMed ID: 29909918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T-cells for cancer therapy.
    Muhammad N; Mao Q; Xia H
    Biotechnol Genet Eng Rev; 2017 Oct; 33(2):190-226. PubMed ID: 29431047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor T cells.
    Zheng R; Chen Y; Zhang Y; Liang S; Zhao X; Wang Y; Wang P; Meng R; Yang A; Yan B
    Front Immunol; 2023; 14():1258156. PubMed ID: 38022548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.